Merck, Bayer Drug Vericiguat Meets Primary Endpoint in Phase 3 Study

Date : 11/18/2019 @ 12:14PM
Source : Dow Jones News
Stock : Bayer AG (BAYN)
Quote : 69.18  0.2 (0.29%) @ 4:35PM

Merck, Bayer Drug Vericiguat Meets Primary Endpoint in Phase 3 Study

Merck (NYSE:MRK)
Historical Stock Chart

1 Month : From Nov 2019 to Dec 2019

Click Here for more Merck Charts.

By Colin Kellaher

 

Merck & Co. (MRK) on Monday said vericiguat, an investigational drug it is developing with Bayer AG (BAYN.XE), met the primary efficacy endpoint in a phase 3 study in patients with worsening chronic heart failure.

The Kenilworth, N.J., drug maker said vericiguat reduced the risk of the composite endpoint of heart failure hospitalization or cardiovascular death in patients with worsening chronic heart failure with reduced ejection fraction compared to placebo when given in combination with available heart failure therapies.

Merck and Germany's Bayer formed a worldwide collaboration in October 2014 in the field of soluble guanylate cyclase modulators such as vericiguat.

Merck said the companies will present the study results at an upcoming medical meeting in 2020.

 

Write to Colin Kellaher at colin.kellaher@wsj.com

 

(END) Dow Jones Newswires

November 18, 2019 06:59 ET (11:59 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.